GSK Puts Faith In Next Gen Respiratory, Real World Studies
Company Seeks Edge Over Rival AZ
A pioneer in the field, can GSK’s investment in real world studies pay off?
You may also be interested in...
Issued with a complete response letter from the FDA, the company says it will now submit newer data showing the combination's effects on exacerbations.
AstraZeneca's R&D leader admits mistakes in earlier failed Phase III trials. A new study will target the high eosinophil sub-group.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.